Daniela Dolciami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniela Dolciami has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Macchiarulo
Department of Pharmaceutical Sciences University of Perugia Perugia Italy
5 shared publications Alice Coletti
Department of Pharmaceutical Sciences, University of Perugia, via del Liceo, 1 - 06123, Perugia, Italy
4 shared publicationsFrancesco Antonio Greco
Dipartimento di Scienze Farmaceutiche, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy
3 shared publications- Andrea Carotti
Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti 48, 06123, Perugia, Italy
2 shared publications Chiara Custodi
Dipartimento di Scienze Farmaceutiche, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy
2 shared publications- Francesca Fallarino
Department of Medicine and Surgery, University of Perugia, Perugia, Italy
2 shared publications
Latest Publications
- Open Access
- 1 September 2018
- Published by SAGE Publications in Natural Product Communications
- Vol. 13 (9)
Microscale Thermophoresis and Docking Studies Suggest Lapachol and Auraptene are Ligands of IDO1
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key target for the development of small molecule immunotherapies in oncology. In this framework, the screening of chemotherapeutic agents to identify compounds binding to IDO1 represents a valuable strategy for the development of multitarget drug candidates that combine synergic immunoregulatory properties to cytotoxic activity. In this study, we report that two natural compounds endowed with anticancer activity, namely lapachol and auraptene, act as IDO1 ligands with dissociation constant (Kd) in the micromolar range of potency. Docking studies provide plausible binding modes of these compounds to the catalytic cleft of IDO1. Our results support the notion that lapachol and auraptene may be considered interesting lead compounds in the immuno-oncology setting.
- 1 September 2018
- Published by SAGE Publications in Natural Product Communications
- Vol. 13 (9)
Open AccessMicroscale Thermophoresis and Docking Studies Suggest Lapachol and Auraptene are Ligands of IDO1
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key target for the development of small molecule immunotherapies in oncology. In this framework, the screening of chemotherapeutic agents to identify compounds binding to IDO1 represents a valuable strategy for the development of multitarget drug candidates that combine synergic immunoregulatory properties to cytotoxic activity. In this study, we report that two natural compounds endowed with anticancer activity, namely lapachol and auraptene, act as IDO1 ligands with dissociation constant (Kd) in the micromolar range of potency. Docking studies provide plausible binding modes of these compounds to the catalytic cleft of IDO1. Our results support the notion that lapachol and auraptene may be considered interesting lead compounds in the immuno-oncology setting.
- 23 January 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (3) , 270-279
Binding Mode and Structure–Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist
Discovered as a modulator of the toxic response to environmental pollutants, aryl hydrocarbon receptor (AhR) has recently gained attention for its involvement in various physiological and pathological pathways. AhR is a ligand‐dependent transcription factor activated by a large array of chemical compounds, which include metabolites of l‐tryptophan (l‐Trp) catabolism as endogenous ligands of the receptor. Among these, 2‐(1′H‐indole‐3′‐carbonyl)thiazole‐4‐carboxylic acid methyl ester (ITE) has attracted interest in the scientific community, being endowed with nontoxic, immunomodulatory, and anticancer AhR‐mediated functions. So far, no information about the binding mode and interactions of ITE with AhR is available. In this study, we used docking and molecular dynamics to propose a putative binding mode of ITE into the ligand binding pocket of AhR. Mutagenesis studies were then instrumental in validating the proposed binding mode, identifying His 285 and Tyr 316 as important key residues for ligand‐dependent receptor activation. Finally, a set of ITE analogues was synthesized and tested to further probe molecular interactions of ITE to AhR and characterize the relevance of specific functional groups in the chemical structure for receptor activity.
- 23 January 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (3) , 270-279
Binding Mode and Structure–Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist
Discovered as a modulator of the toxic response to environmental pollutants, aryl hydrocarbon receptor (AhR) has recently gained attention for its involvement in various physiological and pathological pathways. AhR is a ligand‐dependent transcription factor activated by a large array of chemical compounds, which include metabolites of l‐tryptophan (l‐Trp) catabolism as endogenous ligands of the receptor. Among these, 2‐(1′H‐indole‐3′‐carbonyl)thiazole‐4‐carboxylic acid methyl ester (ITE) has attracted interest in the scientific community, being endowed with nontoxic, immunomodulatory, and anticancer AhR‐mediated functions. So far, no information about the binding mode and interactions of ITE with AhR is available. In this study, we used docking and molecular dynamics to propose a putative binding mode of ITE into the ligand binding pocket of AhR. Mutagenesis studies were then instrumental in validating the proposed binding mode, identifying His 285 and Tyr 316 as important key residues for ligand‐dependent receptor activation. Finally, a set of ITE analogues was synthesized and tested to further probe molecular interactions of ITE to AhR and characterize the relevance of specific functional groups in the chemical structure for receptor activity.
- Open Access
- 3 August 2017
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 9 (12) , 1327-1338
Binding Properties of Different Categories of Ido1 Inhibitors: A Microscale Thermophoresis Study
Inhibition of IDO1 is a strategy pursued in the immune-oncology pipeline for the development of novel anticancer therapies. At odds with an ever-increasing number of inhibitors being disclosed in the literature and patent applications, only very few compounds have hitherto advanced in clinical settings. We have used MicroScale Thermophoresis analysis and docking calculations to assess on a quantitative basis the binding properties of distinct categories of inhibitors to IDO1. Results shed further light on hidden molecular aspects governing the recognition by the enzyme of compounds with different mechanism of inhibition. Results pinpoint specific binding features of distinct inhibitors to IDO1 that offer clues for the design of next-generation inhibitors of the enzyme.
- 3 August 2017
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 9 (12) , 1327-1338
Open AccessBinding Properties of Different Categories of Ido1 Inhibitors: A Microscale Thermophoresis Study
Inhibition of IDO1 is a strategy pursued in the immune-oncology pipeline for the development of novel anticancer therapies. At odds with an ever-increasing number of inhibitors being disclosed in the literature and patent applications, only very few compounds have hitherto advanced in clinical settings. We have used MicroScale Thermophoresis analysis and docking calculations to assess on a quantitative basis the binding properties of distinct categories of inhibitors to IDO1. Results shed further light on hidden molecular aspects governing the recognition by the enzyme of compounds with different mechanism of inhibition. Results pinpoint specific binding features of distinct inhibitors to IDO1 that offer clues for the design of next-generation inhibitors of the enzyme.
- Open Access
- 16 May 2017
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 8 (7) , 1378-1392
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry
Structure–function relationships of IDO1 and structure–activity relationships of inhibitors are discussed with an outlook on next generation IDO1 ligand.
- 16 May 2017
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 8 (7) , 1378-1392
Open AccessAdvances in indoleamine 2,3-dioxygenase 1 medicinal chemistry
Structure–function relationships of IDO1 and structure–activity relationships of inhibitors are discussed with an outlook on next generation IDO1 ligand.
- Open Access
- 19 July 2016
- Published by Wiley in Molecular Informatics
- Vol. 35 (8-9) , 449-459
Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure
In the last decade, indoleamine 2,3‐dioxygenase 1 (IDO1) has attracted a great deal of attention being recognized as key regulator of immunosuppressive pathways in the tumor immuno‐editing process. Several classes of inhibitors have been developed as potential anticancer agents, but only few of them have advanced in clinical trials. Hence, the quest of novel potent and selective inhibitors of the enzyme is still active and mostly pursued by structure‐based drug design strategies based on early and more recent crystal structures of IDO1. Combining docking studies and molecular dynamic simulations, in this work we have comparatively investigated the structural features of each crystal structure of IDO1. The results pinpoint different features in specific crystal structures of the enzyme that may benefit the medicinal chemistry arena aiding the design of novel potent and selective inhibitors of IDO1.
- 19 July 2016
- Published by Wiley in Molecular Informatics
- Vol. 35 (8-9) , 449-459
Open AccessDocking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure
In the last decade, indoleamine 2,3‐dioxygenase 1 (IDO1) has attracted a great deal of attention being recognized as key regulator of immunosuppressive pathways in the tumor immuno‐editing process. Several classes of inhibitors have been developed as potential anticancer agents, but only few of them have advanced in clinical trials. Hence, the quest of novel potent and selective inhibitors of the enzyme is still active and mostly pursued by structure‐based drug design strategies based on early and more recent crystal structures of IDO1. Combining docking studies and molecular dynamic simulations, in this work we have comparatively investigated the structural features of each crystal structure of IDO1. The results pinpoint different features in specific crystal structures of the enzyme that may benefit the medicinal chemistry arena aiding the design of novel potent and selective inhibitors of IDO1.
- 21 November 2014
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 54 (12) , 3373-3383
Ligand Binding and Functional Selectivity of l-Tryptophan Metabolites at the Mouse Aryl Hydrocarbon Receptor (mAhR)
The aryl hydrocarbon receptor (AhR) is a nuclear receptor regulating a wide range of biological and toxicological effects. Metabolites of l-tryptophan are able to bind and activate AhR, providing a link between tryptophan catabolism and a novel mechanism of protective tolerance, referred to as “disease tolerance”. The notion that pharmacologic modulation of genes associated with endotoxin tolerance would be beneficial in clinical settings dominated by acute hyperinflammatory responses to infection thrusts AhR into the limelight as an interesting druggable target. Combining homology modeling, docking studies, and molecular dynamic simulations with mutagenesis experiments and gene profiling, in this work we report that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and two different l-tryptophan metabolites, namely l-Kynurenine and FICZ (6-formylindolo[3,2-b]carbazole), are able to bind to mAhR, exploiting different key interactions with distinct set of fingerprint residues. As a result, they stabilize different conformations of mAhR that, in turn, selectively regulate downstream signaling and transcription of specific target genes. Collectively, these results open new avenues for the design and development of selective AhR modulators that, by targeting specific receptor conformations associated with specific AhR functions, may offer novel therapeutic opportunities in infectious diseases and other morbidity that may be associated with the receptor.
- 21 November 2014
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 54 (12) , 3373-3383
Ligand Binding and Functional Selectivity of l-Tryptophan Metabolites at the Mouse Aryl Hydrocarbon Receptor (mAhR)
The aryl hydrocarbon receptor (AhR) is a nuclear receptor regulating a wide range of biological and toxicological effects. Metabolites of l-tryptophan are able to bind and activate AhR, providing a link between tryptophan catabolism and a novel mechanism of protective tolerance, referred to as “disease tolerance”. The notion that pharmacologic modulation of genes associated with endotoxin tolerance would be beneficial in clinical settings dominated by acute hyperinflammatory responses to infection thrusts AhR into the limelight as an interesting druggable target. Combining homology modeling, docking studies, and molecular dynamic simulations with mutagenesis experiments and gene profiling, in this work we report that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and two different l-tryptophan metabolites, namely l-Kynurenine and FICZ (6-formylindolo[3,2-b]carbazole), are able to bind to mAhR, exploiting different key interactions with distinct set of fingerprint residues. As a result, they stabilize different conformations of mAhR that, in turn, selectively regulate downstream signaling and transcription of specific target genes. Collectively, these results open new avenues for the design and development of selective AhR modulators that, by targeting specific receptor conformations associated with specific AhR functions, may offer novel therapeutic opportunities in infectious diseases and other morbidity that may be associated with the receptor.